drugset / Trial / NCT00523809

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

NCT00523809

Phase 2 Terminated 5 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if giving Avastin (bevacizumab) with standard chemotherapy and a blood stem cell transplant, in patients with an advanced solid tumor, can help to shrink the tumor or slow its growth. The safety of this treatment will also be studied.

Timeline

Start
2007-08
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 10 mg/kg Intravenous
Background Fludarabine Small molecule 25 mg/m2 Intravenous
Background Melphalan Small molecule 70 mg/m2 Intravenous
Background Thymoglobulin Protein / enzyme biologic 2 mg/kg Intravenous